Conference
First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.
Authors
Gettinger SN; Hellmann MD; Shepherd FA; Antonia SJ; Brahmer JR; Chow LQM; Goldman JW; Juergens RA; Borghaei H; Ready N
Volume
33
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
May 20, 2015
Name of conference
51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer
Conference place
IL, Chicago
Conference start date
May 29, 2015
Conference end date
June 2, 2015
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X